获取途径

作者

Xiaoming Wang, Luping Ding, Yongjun Fang, Jie Yan, Ju Gao, Liangchun Yang, Aiguo Liu, Jun Lu, Jingfu Wang, Aijun Zhang, Yijin Gao, Xiuli Ju

作者单位

Affiliations ¹ Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, Shandong Province, China. ² Department of Hematology/Oncology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. ³ Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. ⁴ Department of Pediatrics, West China University Second Hospital of Sichuan University, Chengdu, Sichuan Province, China. ⁵ Department of Pediatric Hematology/Oncology, Xiangya Hospital of Central South University, Changsha, Hunan Province, China. ⁶ Department of Pediatric Hematology/Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei Province, China. ⁷ Department of Hematology/Oncology, Children's Hospital of Soochow University, Soochow, Jiangsu Province, China. ⁸ Department of Pediatric Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. ⁹ Department of Hematology/Oncology, School of Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University, Shanghai, China.

刊名

Cancer medicine

年份

2024

卷号

Vol.13 No.21

页码

e70309

ISSN

2045-7634

关键词

children high‐risk mature B‐NHL risk factors rituximab.

摘要

Backgrounds and aims: Our previous study reported the treatment strategies and outcomes of pediatric B-cell non-Hodgkin's lymphoma in China which showed that children in low-risk groups already have a dramatically favorable prognosis. However, for high-risk groups, the prognosis still needs to be improved. In this study, we aimed to identify the factors influencing prognosis in high-risk groups . Results: Our results revealed that gender, lactate dehydrogenase level, stage at the time of diag...更多

Backgrounds and aims: Our previous study reported the treatment strategies and outcomes of pediatric B-cell non-Hodgkin's lymphoma in China which showed that children in low-risk groups already have a dramatically favorable prognosis. However, for high-risk groups, the prognosis still needs to be improved. In this study, we aimed to identify the factors influencing prognosis in high-risk groups . Results: Our results revealed that gender, lactate dehydrogenase level, stage at the time of diagnosis, and early complete remission achievement were significant factors influencing prognosis . The 3-year EFS rate for R4 group patients without rituximab treatment was only 25.0% ± 20.4%. Among all patients in stage IV, the 5-year EFS rates for those with involvement of only bone marrow or central nervous system were 83.0% ± 4.5%, 81.8% ± 8.2%, but the 5-year EFS rates for those with both BM and CNS involved were only 37.5% ± 15.3% . For stage III patients with LDH ≥ 4N, the 5-year EFS rates for those achieving CR and those not achieving CR after 2 treatment cycle were 88.9% ± 5.2% and 67.9% ± 7.3%. Conclusions: Therefore, R4 group patients benefited from rituximab treatment. However, children at stage III, LDH ≥ 4N not achieving CR after the 2nd treatment cycle, and those with both BM and CNS involved are still at a very high risk of treatment failure. This study serves as a crucial reference for optimizing risk stratification, refining treatment categorizations, and optimizing treatment protocols.收起

文献类型

期刊